

ANDA 77-270

Food and Drug Administration
Rockville MD 20857

OCT 28 2005

TEVA Pharmaceuticals USA
Attention: Philip Erickson,
Senior Director, Regulatory Affairs
1090 Horsham Road
P.O. Box 1090
North Wales, PA 19454

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated September 9, 2004, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Glipizide and Metformin Hydrochloride Tablets 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg.

Reference is also made to your amendments dated May 12, June 6, and September 27, 2005.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Glipizide and Metformin Hydrochloride Tablets 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (Metaglip™ Tablets 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg, respectively, of Bristol-Myers Squibb Company). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Amundson Road
Beltsville, MD 20705


We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

RECEIVED

NOV - 3 2005

TEVA PHARMACEUTICALS, USA
REGULATORY AFFAIRS DEPT

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Gary Buehler" followed by a large flourish and the letters "for".

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research